Analysis of the domestic market of 1,2,4-triazole-containing drugs
DOI:
https://doi.org/10.14739/2409-2932.2022.2.259045Keywords:
domestic market, drug, characteristics of drugs – 1,2,4-triazole derivativesAbstract
The modern market of medicines in Ukraine has the dynamics of constant development. At the same time, the dynamics of the pharmaceutical market depend entirely on the welfare of the population. Current features of quarantine restrictions have caused a number of distortions in drug consumption. Thus, after the introduction of quarantine in March 2020, part of the population panicked, which forced them to stockpile vital goods. At this time, there was a significant increase in sales of drugs, including antiviral, antiseptic, and disinfectant activity. The dynamics of drug balances on the shelves reached +50 %. However, there was a sharp decline in consumption between June-October 2020 and April 2021 due to the full effect of quarantine restrictions and March-April 2022 due to martial law in Ukraine. Today, the rate of purchases and balances of medicines on the shelves of pharmacies exceeds the rate of growth of their sales.
The aim of the work is to conduct research and provide a description of the range of the national market of domestic 1,2,4-triazole-containing drugs.
Materials and methods. The following methods were used in the work: analytical, information retrieval, descriptive, and generalization. The materials of the research were literature sources that contain information on the registration of domestic 1,2,4-triazole-containing drugs in Ukraine at present.
Results. The search, analysis, characterization, and generalization of domestic drugs – derivatives of 1,2,4-triazoles were carried out. It was established that the Ukrainian market was moderately saturated with 1,2,4-triazole-containing drugs of domestic production based on the study of available information and scientific research. The drugs have a fairly wide range of applications in medicine, have different mechanisms of action, belong to different pharmacotherapeutic groups, and were used in veterinary practice and the agro-industrial economy.
Conclusions. Elaboration, analysis, systematization, comparison, and generalization of modern sources of information indicated a fairly high biological activity of 1,2,4-triazole derivatives, a wide range of applications, and moderate saturation of the national market with 1,2,4-triazole-containing drugs.
References
Goadsby, P. J., Lipton, R. B., & Ferrari, M. D. (2002). Migraine--current understanding and treatment. The New England journal of medicine, 346(4), 257-270. https://doi.org/10.1056/NEJMra010917
Vyas, K. P., Halpin, R. A., Geer, L. A., Ellis, J. D., Liu, L., Cheng, H., Chavez-Eng, C., Matuszewski, B. K., Varga, S. L., Guiblin, A. R., & Rogers, J. D. (2000). Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. Drug metabolism and disposition: the biological fate of chemicals, 28(1), 89-95.
Sciberras, D. G., Polvino, W. J., Gertz, B. J., Cheng, H., Stepanavage, M., Wittreich, J., Olah, T., Edwards, M., & Mant, T. (1997). Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. British journal of clinical pharmacology, 43(1), 49-54. https://doi.org/10.1111/j.1365-2125.1997.tb00032.x
Goldberg, M. R., Lee, Y., Vyas, K. P., Slaughter, D. E., Panebianco, D., Ermlich, S. J., Shadle, C. R., Brucker, M. J., McLoughlin, D. A., & Olah, T. V. (2000). Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjects. Journal of clinical pharmacology, 40(1), 74-83. https://doi.org/10.1177/00912700022008595
Ferrari, M. D., Goadsby, P. J., Roon, K. I., & Lipton, R. B. (2002). Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia : an international journal of headache, 22(8), 633-658. https://doi.org/10.1046/j.1468-2982.2002.00404.x
Merck & Co Inc. (2003) Maxalt® (rizatriptan benzoate tablets) and Maxalt-MLT® (rizatriptan benzoate orally disintegrating tablets): United States prescribing information. New Jersey, USA: Merck & Co, Inc.
Pearson, M. M., Rogers, P. D., Cleary, J. D., & Chapman, S. W. (2003). Voriconazole: a new triazole antifungal agent. The Annals of pharmacotherapy, 37(3), 420-432. https://doi.org/10.1345/aph.1C261
Espinel-Ingroff, A. (1998). In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. Journal of clinical microbiology, 36(1), 198-202. https://doi.org/10.1128/JCM.36.1.198-202.1998
Johnston, D., Zhon, X., & Fukuoka, T. (1995). Voriconazole is highly active against the 14α demethylase of Candida krusei. Proceedings of the 39th ICAAC, San Francisco.
Johnson, E. M., Szekely, A., & Warnock, D. W. (1998). In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. Journal of Antimicrobial Chemotherapy, 42(6), 741-745. https://doi.org/10.1093/jac/42.6.741
Roila, F., Ruggeri, B., Ballatori, E., Del Favero, A., & Tonato, M. (2014). Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: A randomized double-blind study. Journal of Clinical Oncology, 32(2), 101-106. https://doi.org/10.1200/JCO.2013.51.4547
Lohr, L. (2008). Chemotherapy-induced nausea and vomiting. Cancer journal (Sudbury, Mass.), 14(2), 85-93. https://doi.org/10.1097/PPO.0b013e31816a0f07
Di Maio, M., Gallo, C., & Perrone, F. (2008). Analisi congiunta degli studi di fase III con palonosetron nella prevenzione dell'emesi da chemioterapia moderatamente emetogena [Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy]. Tumori, 94(2), 14-22.
Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J., Powell, E., Riordan, S., Sheridan, D., Smedile, A., Fragomeli, V., Müller, T., Bahlo, M., Stewart, G. J., Booth, D. R., & George, J. (2009). IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature genetics, 41(10), 1100-1104. https://doi.org/10.1038/ng.447
Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., Sulkowski, M., McHutchison, J. G., & Goldstein, D. B. (2009). Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 461(7262), 399-401. https://doi.org/10.1038/nature08309
Rauch, A., Kutalik, Z., Descombes, P., Cai, T., Di Iulio, J., Mueller, T., Bochud, M., Battegay, M., Bernasconi, E., Borovicka, J., Colombo, S., Cerny, A., Dufour, J. F., Furrer, H., Günthard, H. F., Heim, M., Hirschel, B., Malinverni, R., Moradpour, D., Müllhaupt, B., … Swiss HIV Cohort Study (2010). Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 138(4), 1338-1345.e13457. https://doi.org/10.1053/j.gastro.2009.12.056
Gonzalez, S. A., & Keeffe, E. B. (2011). IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. Gastroenterology & hepatology, 7(6), 366-373.
Taylor, J. R., Vazquez, C. M., & Campbell, K. M. (2006). Pharmacologic management of chronic insomnia. Southern medical journal, 99(12), 1373-1377. https://doi.org/10.1097/01.smj.0000243131.25116.bd
Kompendium - likarski preparaty [Compendium. Medicines] [in Ukrainian]. https://compendium.com.ua/uk
Geisler, J., Helle, H., Ekse, D., Duong, N. K., Evans, D. B., Nordbø, Y., Aas, T., & Lønning, P. E. (2008). Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clinical cancer research, 14(19), 6330-6335. https://doi.org/10.1158/1078-0432.CCR-07-5221
Smith, I., Yardley, D., Burris, H., De Boer, R., Amadori, D., McIntyre, K., Ejlertsen, B., Gnant, M., Jonat, W., Pritchard, K. I., Dowsett, M., Hart, L., Poggio, S., Comarella, L., Salomon, H., Wamil, B., & O'Shaughnessy, J. (2017). Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. Journal of clinical oncology, 35(10), 1041-1048. https://doi.org/10.1200/JCO.2016.69.2871
Ellis, M. J., Suman, V. J., Hoog, J., Lin, L., Snider, J., Prat, A., Parker, J. S., Luo, J., DeSchryver, K., Allred, D. C., Esserman, L. J., Unzeitig, G. W., Margenthaler, J., Babiera, G. V., Marcom, P. K., Guenther, J. M., Watson, M. A., Leitch, M., Hunt, K., & Olson, J. A. (2011). Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. Journal of clinical oncology, 29(17), 2342-2349. https://doi.org/10.1200/JCO.2010.31.6950
Gupta, A. K., Ryder, J. E., & Johnson, A. M. (2004). Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. The British journal of dermatology, 150(3), 537-544. https://doi.org/10.1046/j.1365-2133.2003.05728.x
Heikkilä, H., & Stubb, S. (1995). The prevalence of onychomycosis in Finland. The British journal of dermatology, 133(5), 699-703. https://doi.org/10.1111/j.1365-2133.1995.tb02741.x
Workowski, K. A., Bolan, G. A., & Centers for Disease Control and Prevention (2015). Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 64(RR-03), 1-137.
Dharmik, P. G., Gomashe, A. V., & Upadhyay, V. G. (2013). Susceptibility pattern of various azoles against Candida species causing vulvovaginal candidiasis. Journal of obstetrics and gynaecology of India, 63(2), 135-137. https://doi.org/10.1007/s13224-012-0280-3
Pfaller, M. A., Diekema, D. J., Rinaldi, M. G., Barnes, R., Hu, B., Veselov, A. V., Tiraboschi, N., Nagy, E., & Gibbs, D. L. (2005). Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. Journal of clinical microbiology, 43(12), 5848-5859. https://doi.org/10.1128/JCM.43.12.5848-5859.2005
Bushueva, I. V., Parkhomenko, L. I., Knysh, Ye. G., & Panasenko, O. I. (2014). Zastosuvannia morfolinii 2-[5-(pirydyn-4-il)-1,2,4-triazol-3-iltio]atsetatu dlia likuvannia i profilaktyky deiakykh zakhvoriuvan [Application of the morpholines of 2-[5-(pyridin-4-yl)-1,2,4-triazol-3-ylthio] acetates for the treatment and prevention of some diseases]. Zaporozhye medical journal, (2), 97-99. [in Ukrainian].
Parchenko, V. V. (2014). Syntez, peretvorennia, fizyko-khimichni ta biolohichni vlastyvosti v riadi 5-furylzamishchenykh 1,2,4-triazol-3-tioniv (Dis. dokt. farm. nauk) [Synthesis, transformation, physico-chemical and biological properties in the number of 5-furylsubstituted 1,2,4-triazole-3-thiones (Doctoral dissertation)]. Zaporizhzhia State Medical University, Zaporizhzhia. [in Ukrainian].
Parchenko, V. V. (2006). Syntez, fizyko-khimichni ta biolohichni vlastyvosti pokhidnykh 1,2,4-triazol-3-tionu, yaki mistiat yadro furanu [Synthesis, physicochemical and biological properties of 1,2,4-triazole-3-thione derivatives containing furan nucleus (Dissertation of the Candidate of Pharmaceutical Sciences). Kyiv [in Ukrainian].
Tryfuzol-NEO [website] [in Ukrainian]. http://trifuzol-neo.com/
Martynyshyn, V. P., Hunchak, V. M., Yaroshenko, А. І., & Parchenko, V. V. (2019). Chromagraphic research of liniment, which active sub-stance belongs to new derivatives of 1, 2, 4-triazole. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 10(1), 806-811. https://doi.org/10.13140/RG.2.2.35871.61609
Shcherbyna, R., Parchenko, V., Martynyshyn, V., & Hunchak, V. (2018). Evaluation of acute and subacute toxicity of oil liniment based on 4-((5-(decylthio)-4-methyl-4H-1,2,4-triazol-3-yl)methyl)morpholine. Ankara Universitesi Eczacilik Fakultesi Dergisi, 42(1), 43-52. https://doi.org/10.1501/Eczfak-0000000601
Fortys Komby [website] [in Ukrainian]. https://fortis-combi.com
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
